ATTR amyloidosis is a rare, progressive disease caused by the accumulation of transthyretin protein

ATTR Amyloidosis: Disease Overview: ATTR amyloidosis is a rare, progressive disease caused by the accumulation of transthyretin protein deposits in tissues and organs, leading to severe health complications including cardiomyopathy and neuropathy.Innovative Therapies: Attralus is focused on developing therapies that target the underlying cause of ATTR amyloidosis, aiming to halt or reverse the disease’s progression. Attralus utilizes its proprietary ATTRect™ platform to identify and develop novel therapies for ATTR amyloidosis. This platform is designed to enhance the understanding of the disease and improve treatment outcomes.Lead Product Candidates: Attralus is advancing several product candidates through clinical development, including novel treatments that aim to reduce amyloid deposits and improve patient outcomes.